中国保健营养（中旬刊）
中國保健營養（中旬刊）
중국보건영양（중순간）
China Hwalth Care & nutrition
2014年
7期
4517-4517
,共1页
稳心颗粒%慢性充血性心力衰竭%心房纤颤%疗效
穩心顆粒%慢性充血性心力衰竭%心房纖顫%療效
은심과립%만성충혈성심력쇠갈%심방섬전%료효
wenxin Pelet%Congestive Heart Failure%Atrial Fibrrilation%effect
目的：探讨稳心颗粒治疗慢性充血性心力衰竭并心房纤颤疗效及安全性。方法：选择80例CHF并AF住院患者，随机分为对照组（常规治疗）40例，治疗组（稳心颗粒+常规治疗）40例。治疗8周，观察用药前后心率及心功能变化。结果：治疗后两组患者心功能都有好转，治疗组优于对照组（P<0.05）。治疗组超声心动图(SV)、心指数（CL）、左室射血分数（EF）等心功能参数有明显改善，左室收缩期末内径（LVEsd），左室舒张期末内径（LVEDd）缩小，心率减慢（P<0.05）。结论：稳心颗粒治疗慢性充血性心力衰竭并心房纤颤耐受性好，安全有效。
目的：探討穩心顆粒治療慢性充血性心力衰竭併心房纖顫療效及安全性。方法：選擇80例CHF併AF住院患者，隨機分為對照組（常規治療）40例，治療組（穩心顆粒+常規治療）40例。治療8週，觀察用藥前後心率及心功能變化。結果：治療後兩組患者心功能都有好轉，治療組優于對照組（P<0.05）。治療組超聲心動圖(SV)、心指數（CL）、左室射血分數（EF）等心功能參數有明顯改善，左室收縮期末內徑（LVEsd），左室舒張期末內徑（LVEDd）縮小，心率減慢（P<0.05）。結論：穩心顆粒治療慢性充血性心力衰竭併心房纖顫耐受性好，安全有效。
목적：탐토은심과립치료만성충혈성심력쇠갈병심방섬전료효급안전성。방법：선택80례CHF병AF주원환자，수궤분위대조조（상규치료）40례，치료조（은심과립+상규치료）40례。치료8주，관찰용약전후심솔급심공능변화。결과：치료후량조환자심공능도유호전，치료조우우대조조（P<0.05）。치료조초성심동도(SV)、심지수（CL）、좌실사혈분수（EF）등심공능삼수유명현개선，좌실수축기말내경（LVEsd），좌실서장기말내경（LVEDd）축소，심솔감만（P<0.05）。결론：은심과립치료만성충혈성심력쇠갈병심방섬전내수성호，안전유효。
to discuss the effective and safety of the wenxin Pelet in Patients with Congestive Heart Failure and Atrial Fibirrilation.Methods:80 patients with Congestive Heart Failure and Atrial Fibrrilation(AF) in hospital were randomly divided into two groups :therapy group (n=40) and control group(n=40).The two groups are both receiving the routine treatment ,besides thant the therapy group administrated additional wenxin pelets .After eight-week treatment , observing the changement of the heart rate and the cardiac function.Result:After treatment, the cardiac function in the two groups was improved ,and the improvement in treatment group was superior than that in the control group(P<0.05).In the therapy group , the skroke volume(SV), cardiac index(CL),and left ventricular election fraction(EF) were significantly improved ,and inside diameters of the left ventricle at the end-diastolic phasc and the end-systolic phase reduced significantly ,and the heart rate desecended(P<0.05).Conclusion:It issafe and effective of Wenxin Pelet during the treatment in patients with Congestive Heart Failure and Atrial Fibrrilation.
